|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
ISCTM Pushes for Innovation in the Development of Novel Therapies for CNS Disorders
2/3/2012 7:27:03 AM
WASHINGTON--(BUSINESS WIRE)--In a continuation of its mission to address the crisis in CNS drug development, the International Society for CNS Clinical Trials and Methodology (ISCTM) will gather this month for its annual meeting in Washington, D.C. Despite large unmet clinical needs, CNS drugs continue to take longer to develop than other therapies, longer to be reviewed by the FDA, and are nearly 50% more likely to fail the most costly and time consuming step in development, Phase 3 clinical trials. Moreover, increasing concerns about conflict of interest have discouraged active collaborations among academic researchers, their pharmaceutical industry colleagues, and regulators. To address these systemic issues, ISCTM acts as a non-promotional forum for cross-disciplinary collaboration among these groups. Through ongoing working groups and semi-annual meetings, ISCTM strives to advance CNS clinical trials methods that are innovative, scientifically sound, ethical, and feasible.
|
|
|
|
|
|
|
|
|
|
|